Enders B, Hundt E, Knapp B
Behringwerke AG, Research Laboratories, Marburg, Germany.
Mem Inst Oswaldo Cruz. 1992;87 Suppl 3:413-22. doi: 10.1590/s0074-02761992000700070.
The genus Aotus spp. (owl monkey) is one of the WHO recommended experimental models for Plasmodium falciparum blood stage infection, especially relevant for vaccination studies with asexual blood stage antigens of this parasite. For several immunization trials with purified recombinant merozoite/schizont antigens, the susceptible Aotus karyotypes II, III, IV and VI were immunized with Escherichia coli derived fusion proteins containing partial sequences of the proteins MSAI (merozoite surface antigen I), SERP (serine-stretch protein) and HRPII (histidine alanine rich protein II) as well as with a group of recombinant antigens obtained by an antiserum raised against a protective 41 kD protein band. The subcutaneous application (3x) of the antigen preparations was carried out in intact animals followed by splenectomy prior to challenge, in order to increase the susceptibility of the experimental hosts to the parasite. A partial sequence of HRPII, the combination of three different fusion proteins of the 41 kD group and a mixture of two sequences of SERP in the presence of a modified Al(OH)3 adjuvant conferred significant protection against a challenge infection with P. falciparum blood stages (2-5 x 10(6)) i. RBC). Monkeys immunized with the MS2-fusion protein carrying the N-terminal part of the 195 kD precursor of the major merozoite surface antigens induced only marginal protection showing some correlation between antibody titer and degree of parasitaemia. Based on the protective capacity of these recombinant antigens we have expressed two hybrid proteins (MS2/SERP/HRPII and SERP/MSAI/HRPII) in E. coli containing selected partial sequences of SERP, HRPII and MSAI. Antibodies raised against both hybrid proteins in rabbits and Aotus monkeys recognize the corresponding schizont polypeptides. In two independent immunization trials using 13 animals (age 7 months to 3 years) we could show that immunization of Aotus monkeys with either of the two hybrid proteins administered in an oil-based well tolerated formulation protected the animals from a severe experimental P. falciparum (strain Palo Alto) infection.
夜猴属(Aotus spp.)(夜猴)是世界卫生组织推荐的用于恶性疟原虫血液阶段感染的实验模型之一,尤其适用于针对该寄生虫无性血液阶段抗原的疫苗接种研究。在多项使用纯化重组裂殖子/裂殖体抗原的免疫试验中,对易感的夜猴核型II、III、IV和VI用大肠杆菌衍生的融合蛋白进行免疫,这些融合蛋白包含疟原虫裂殖子表面抗原I(MSAI)、丝氨酸延伸蛋白(SERP)和富含组氨酸丙氨酸蛋白II(HRPII)的部分序列,以及一组通过针对一条保护性41 kD蛋白条带产生的抗血清获得的重组抗原。抗原制剂在完整动物中进行皮下注射(3次),然后在攻击前进行脾切除术,以增加实验宿主对寄生虫的易感性。HRPII的部分序列、41 kD组的三种不同融合蛋白的组合以及在改良氢氧化铝佐剂存在下的SERP的两种序列的混合物,对恶性疟原虫血液阶段(2 - 5×10⁶个感染红细胞)的攻击感染提供了显著保护。用携带主要裂殖子表面抗原195 kD前体N端部分的MS2融合蛋白免疫的猴子仅诱导了微弱的保护,抗体滴度与寄生虫血症程度之间存在一定相关性。基于这些重组抗原的保护能力,我们在大肠杆菌中表达了两种包含SERP、HRPII和MSAI选定部分序列的杂合蛋白(MS2/SERP/HRPII和SERP/MSAI/HRPII)。在兔和夜猴中针对这两种杂合蛋白产生的抗体识别相应的裂殖体多肽。在两项使用13只动物(年龄7个月至3岁)的独立免疫试验中,我们发现用两种杂合蛋白中的任何一种以油基且耐受性良好的制剂免疫夜猴,可保护动物免受严重的实验性恶性疟原虫(帕洛阿尔托株)感染。